Bio-Techne And Hall Of Famer Cal Ripken Jr -Announce Partnership To Raise Awareness And Education To Empower Men With Prostate Cancer
MINNEAPOLIS, Sept. 8, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH)
today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new
partnership with Hall of Famer and baseball's all-time "Iron Man", Cal Ripken Jr. This year
marks 25 years since Ripken played in his 2,131st consecutive game, eclipsing the thought
to be unbreakable record of 2,130 set by the legendary Lou Gehrig. Recently the 21-year
Major League veteran divulged that earlier this year he was diagnosed with and successfully
treated for prostate cancer. Today Ripken, 60, is leading a national effort with Exosome
Diagnostics to build education and awareness of the ExoDx ™ Prostate test, encourage men to proactively take action and be aware of their prostate health. The ExoDx™ Prostate (EPI) test played an important role in the management of Cal's prostate cancer.
One in nine American men will be diagnosed with prostate cancer during their lifetime.
Prostate cancer (PCa) is the second leading cause of cancer death among American men
and is the most commonly diagnosed cancer. The American Cancer Society estimates that
over 191,000 men will be diagnosed with prostate cancer in 2020 and projects that ~33,000
men will die from the disease. Currently, nearly 3.6 million American men are living with the
disease – only slightly less than the population of Los Angeles.
The EPI test is a urine-based genomic test that helps inform the prostate biopsy decision.
This liquid biopsy test recently received coverage for the VA Healthcare system under the
General Services Administration (GSA) award, received a positive coverage decision from
Medicare, and is included in the National Comprehensive Cancer Network (NCCN)
guidelines for early detection in men for both initial and repeat biopsy. It is performed by
Exosome Diagnostics in its CLIA, ISO, and NY certified and CAP-accredited laboratory
located in Waltham, Massachusetts. The EPI test is a risk assessment tool that assists
physicians and their patients with determining if a prostate biopsy is needed when presented
with an ambiguous PSA test result, thereby reducing complications from unnecessary and
invasive procedures. ExoDx Prostate is now available with an At-Home Collection kit,
enabling patients unable to see a healthcare professional or preferring to collect their sample
at home access to the test.
Cal Ripken Jr. and Exosome Diagnostics will launch the newly formed partnership during the
month of September, which is notably Prostate Cancer Awareness month, by speaking out
about his story through a series of videos and articles. Mr. Ripken and his personal physician and urologist, Dr. Ronald Tutrone of Chesapeake Urology in Baltimore, MD, will host a live speaking webinar event on September 29, 12:00-1:00 pm ET. The event requires advance registration and is available for replay following the event; replay details will be available on Exosomedx.com. Cal Ripken Jr. and Dr. Ronald Tutrone are expected to discuss Mr. Ripken's personal prostate cancer journey, including the realization that the Iron Man became susceptible to the disease without traditional signs and symptoms, and the moment of clarity he had with his ExoDx Prostate test result.
"We are elated that Mr. Ripken survived prostate cancer and that our ExoDx Prostate test
made a difference in the care and treatment of his condition," said Chuck Kummeth,
President and Chief Executive Officer of Bio-Techne. "He not only gave his heart and soul to
the game of baseball, but is now willing to leverage his highly visible platform to make an
impact on men's lives by sharing his personal prostate cancer experience and how the
ExoDx Prostate test impacted his journey."
Ripken added, "When I was first diagnosed, I had all of the reactions most people had –
concern, fear, uncertainty. Fortunately, Dr. Tutrone and my medical team were fantastic and
because of the ExoDx Prostate test, I chose to have my biopsy and caught my cancer in the
very early stages. After recovery I thought this would be an opportunity to utilize the platform
that baseball has provided me to encourage others to take this simple test and work with
their doctors to determine the best course of action."
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality
purified proteins and reagent solutions - notably cytokines and growth factors,
antibodies, immunoassays, biologically active small molecule compounds, tissue culture
reagents and T-Cell activation technologies. Bio-Techne's product portfolio also includes
protein analysis solutions, sold under the ProteinSimple brand name, offering researchers
efficient and streamlined options for automated western blot and multiplexed ELISA
workflow. These reagent and protein analysis solutions are sold to biomedical researchers
as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-
Techne also develops and manufactures diagnostic products including FDA-regulated
controls, calibrators, blood gas and clinical chemistry controls and custom assay
development on dedicated clinical instruments. Bio-Techne's genomic tools include
advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use, sold
under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays,
including the ExoDxTM Prostate test (EPI) for prostate cancer diagnosis. These diagnostic
and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-
Techne products are integral components of scientific investigations into biological
processes and molecular diagnostics, revealing the nature, diagnosis, etiology and
progression of specific diseases. They aid in drug discovery efforts and provide the means
for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-
Techne generated approximately $739 million in net sales in fiscal 2020 and has
approximately 2,300 employees worldwide.
About Cal Ripken, Jr.
Cal Ripken, Jr. is a member of the National Baseball Hall of Fame and played his entire 21-
year Major League career with his hometown Baltimore Orioles. He was a 19-time American
League All-Star, a two-time American League Most Valuable Player and two-time All-Star
Game MVP. He is one of ten players in history with more than 3,000 hits and 400 homeruns. Since retirement Ripken has built a youth baseball business and a national non-profit organization. Ripken Baseball runs tournament destination sites called "The Ripken Experience" in his hometown of Aberdeen, MD, Myrtle Beach, SC, Pigeon Forge, TN and at Disney's Wide World of Sports complex in Orlando, FL. In 2001 he and his family started the Cal Ripken, Sr. Foundation in honor of the family's patriarch. Today the foundation serves underserved youth across the country through programs such as Badges for Baseball and the construction of Youth Development Parks that provide kids with safe places to play and learn. In 2020 the foundation will impact over 1 Million kids nationwide and will built its 100th Youth Development Park. In addition, Ripken is a best-selling author,
an accomplished corporate speaker and a popular corporate spokesperson. Ripken is also
a Public Diplomacy Envoy for the U.S. State Department and since 2007 he has made
goodwill trips to China, Japan, Nicaragua and the Czech Republic.
For Exosome Diagnostics and Bio-Techne
Contact: David Clair, Senior Director, Investor Relations & Corporate Development
For Cal Ripken, Jr.
SOURCE Bio-Techne Corporation